{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"MeiraGTx Holdings plc"},"Symbol":{"label":"Symbol","value":"MGTX"},"Address":{"label":"Address","value":"450 EAST 29TH STREET,14TH FLOOR, NEW YORK, New York, 10016, United States"},"Phone":{"label":"Phone","value":"+1 646 860-7985"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, United Kingdom, and European Union."},"CompanyUrl":{"label":"Company Url","value":"https://www.meiragtx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Alexandria Forbes","title":"President, Chief Executive Officer & Director"},{"name":"Richard Giroux","title":"Chief Operating & Financial Officer"},{"name":"Robert K. Zeldin","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}